News & Updates
Filter by Specialty:
Erdafitinib prevents recurrence in high-risk NMIBC
04 Feb 2024
byStephen Padilla
Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.
Erdafitinib prevents recurrence in high-risk NMIBC
04 Feb 2024Amivantamab plus chemo improves survival in advanced NSCLC
03 Feb 2024
byStephen Padilla
Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.